On a panel of five cervical cancer cell lines, the combination of delanzomib plus Dox was able to accumulate levels of p53 where p53 was initially unnoticeable and upregulate p53 transcriptional targets p21, PUMA, and Noxa to a greater degree than just single treatment of delanzomib or Dox alone (Figure 4A). Here, CDKN1A is linked to cervical carcinoma.